Chronic airflow limitation in developing countries: Burden and priorities

International Journal of COPD

Volumn 2, Issue 2, 2007, Pages 141-150

  Aït Khaled, Nadia ^a   Enarson, Donald A ^a   Ottmani, Salah ^b   El Sony, Asma ^c   Eltigani, Mai ^c   Sepulveda, Ricardo ^d  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Epidemiological Laboratory   (Sudan)

^d National Institute of Respiratory Diseases   (Chile)

Author keywords

Air flow limitation; Asthma; COPD; Cost effectiveness; Developing countries; Intervention

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLUCOCORTICOID; IPRATROPIUM BROMIDE; SALBUTAMOL; STEROID;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INDUSTRIALIZATION; MONOTHERAPY; MORTALITY; PATIENT CARE; PREVALENCE; RESOURCE MANAGEMENT; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SMOKING; SOCIAL STATUS;

ADOLESCENT; ADULT; ASTHMA; BRONCHIECTASIS; COST OF ILLNESS; DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; GUIDELINE ADHERENCE; HEALTH CARE COSTS; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INTERNATIONAL COOPERATION; LUNG DISEASES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGRAM DEVELOPMENT; PUBLIC HEALTH; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY SYSTEM AGENTS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 34547647846     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Adams RJ, Fuhlbrigge A, Finkenelstein JA, et al. 2001. Impact of inhaled anti-inflammatory therapy on hospitalisations and emergency department visits for children with asthma. Pediatrics, 107:706-11.
2. Adams NP, Bestall JB, Malouf R, et al. 2005a. Beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev, 1:CD002738.
3. Adams NP, Bestall JM, Lasserson TJ, et al. 2005b. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev, 2:CD002310.
4. Adams NP, Jones PW. 2006. The dos-response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews. Respir Med, 100:1297-306.
5. Aït-Khaled N, Auregan G, Bencharif N, et al. 2000. Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis, 4:268-71.
6. Aït-Khaled N, Enarson DA, Bousquet J. 2001. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ, 79:971-9.
7. Aït-Khaled N, Chaulet P, Enarson DA, et al. 2002. Clinical management of clinical obstructive pulmonary disease. In: Similowski T, Derenne P. (eds). Epidemiology and management of stable chronic obstructive pulmonary disease in Africa. New York: Marcel Dekker, 43:1007-30.
8. Aït-Khaled N, Enarson DA. 2005. Management of asthma. A guide to the essentials of good clinical practice. 2nd ed. Paris, France: International Union Against Tuberculosis and Lung Disease. URL: http://www.iuatld.org.
9. Aït-Khaled N, Enarson DA, Bencharif N, et al. 2006a. Implementation of asthma guidelines in health centres of several developing countries. Int J Tuberc Lung Dis, 10:104-9.
10. Aït-Khaled N. 2006. Favoriser l'accessibilité aux médicaments essentiels de l'asthme. Rev Mal Resp, 23:10S76-10S79.
11. Aït-Khaled N, Enarson DA, Bencharif N, et al. 2006b. Treatment outcome of asthma after one year follow-up in health centres of several developing countries. Int J Tuberc Lung Dis, 10:911-16.
12. Amos A. 1996. Women and smoking: a global issue. World Health Stat Q, 49:127-33.
13. Anyangwe SC, Mtonga C, Chirwa B. 2006. Health inequities, environmental insecurity and the attainments of the millennium development goals in sub-Saharan Africa: The case study of Zambia. Int J Environ Res Public Health, 3:217-27
14. Appleton S, Poole P, Smith B, et al. 2001. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev, 4:CD001104.
15. Appleton S, Jones T, Poole P, et al. 2006. Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD001387.
16. Barr RG, Bourbeau J, Camargo CA, et al. 2005. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2:CD002876.
17. Bayer R, Stuber J. 2006. Tobacco control, stigma, and public health: rethinking the relations. Am J Public Health, 96:47-50
18. Beasley R, Keil U, Von Mutius E, et al; ISAAC Steering Committee. 1998. Worldwide variation in the prevalence of asthma, allergic rhinoconjonctivitis and atopic eczema symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Lancet, 351:1225-32.
19. Bakke S, Baste V, Hanoa R, et al. 1991. Prevalence of obstructive lung disease in general population: relation to occupational title and exposure to some airborne agents. Thorax, 46:863-70.
20. Baris E, Ezzati M. 2004. Should interventions to reduce respirable pollutants be linked to tuberculosis control programmes? BMJ, 329:1090-3
21. Bateman ED, Boushey HA, Bousquet J, et al; GOAL Investigators Group. 2004. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med, 170:836-44.
22. Billo N. 2004. Do we need an asthma drug facility? Int J Tuberc Lung Dis, 8:391.
23. Billo N. 2006. ADF from concept to reality. Int J Tuber Lung Dis, 10:709.
24. Bousquet J, Ndiaye M, Aït-Khaled N, et al. 2003. Management of chronic respiratory and allergic diseases in developing countries. Focus on sub-Saharan Africa. Allergy, 58:265-83.
25. Bousquet J, Van Cauwenberg P, Khaltaev N, et al. 2001. ARIA workshop report in collaboration with WHO. J Allergy Clin Immunol, 108(5 Suppl):S147-334.
26. Calverley PM, Pauwels R, Vestbo J, et al; Trial of Inhaled steroids and long acting beta 2 agonists, study group. 2003a. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361:449-56.
27. Calverley PM, Boonsawat W, Cseke Z, et al. 2003b. Maintenance therapy with budesonide and fomoterol in chronic obstructive disease. Eur Respir J, 22:912-19.
28. Castro M, Zimmerman NA, Crocker S, et al. 2003. Asthma intervention program prevents readmissions in high healthcare users. Am J Respir Crit Care, 168:1095-9.
29. Chan-Yeung M, Aït-Khaled N, White N, et al. 2004. Management of COPD in Asia and Africa. Int Union Tuberc Lung Dis, 8:159-70.
30. Chapple A, Ziebland S, McPherson A. 2004. Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ, 328:1470.
31. Enarson DA. Aït-Khaled N. 1999. Cultural barriers to asthma management. Pediatr Pulmonol, 28:297-300.
32. Enarson DA. 1998. Lung health and the International Union Against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis, 2:969-70.
33. [ECRHS] European Community Respiratory Health Survey. 1996. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medications in the European Community Respiratory Health Survey (ECRHS). Eur Respir J, 9:687-95.
34. Fiore M.C, Bailey WC, Cohen SJ, et al. 2000. Treating tobacco use and dependance. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services.
35. Friedman M, Serby CW, Hilleman DE, et al. 1999. Pharmacoeconomic Evaluation of a combination of Ipratropium Plus Albuterol Compared With Ipratropium and albuterol alone in COPD. Chest, 115:635-41.
36. Fournier M, Tonnel AB, Housset B, et al. 2005. Economic burden of COPD in France: The Scope Study [French]. Rev Mal Respir, 22:247-55.
37. Gartlehner G, Hansen RA, Carson SS, et al. 2006. Efficacy and safety of inhaled corticosteroids in patients with COPD. A systematic review and meta-analysis of health outcomes. Ann Fam Med, 4:253-62.
38. Gelders S, Ewen M, Noguchi N, et al. 2006. Price, availability and affordability. An international comparison of chronic disease medicines [online]. Accessed on February 2, 2007. Geneva: WHO, Health Action International. URL: http://mednet3.who.int/medprices/CHRONIC.pdf.
39. [GINA] Global Initiative for Asthma. 2005. Global strategy for asthma management and prevention. NHLBI/WHO workshop report [online]. Accessed on February 2, 2007. NIH publication number 95-3659. Revision 2005. URL: http://www.gina.com/.
40. [GOLD] Global Initiative for Chronic Obstructive Lung Disease. 2005. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. Accessed on February 2, 2007. NIH, NHLBI publication Number 2701, April 2001. Updated 2005. URL: http://www.goldcopd.org/.
41. Gulsvik A. 1979. Prevalence and manifestations of obstructive lung disease in the city of Oslo. Scand J Respir Dis, 60:286-96.
42. Halpin DM. 2006. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac, 3:227-33.
43. Lai CKW, De Guia TS, Kim YY, et al. 2003. Asthma control in Asia-Pacific Study. J Allergy Clin Immunol, 111:263.
44. Lalloo UG, McIvor RA. 2006. Management of chronic asthma in adults in diverse regions of the world. Int Union Tuberc Lung Dis, 10:474-83.
45. Lange P, Groth S, Nyboe J, et al. 1989. Chronic obstructive lung disease in Copenhagen: cross-sectional, epidemiological aspects. J Intern Med, 226:25-32.
46. Lopez AD, Mathers CD, Ezzati M, et al. 2006. Global and regional burden of diseases and risk factors, 2001: systematic analysis of population health data. Lancet, 367:1747-57.
47. Mannino DM, Gagnon RC, Petty TL, et al. 2000. Obstructive lung disease and low lung function in adults in the United States: data. from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med, 160:1683-9.
48. Marco-Jordan L, Martin-Berra J, Inigo MC, et al. 1998. Enfermedad pulmonar obstructiva cronica en la poblacion general: estudio epidemiologico realizado en Guipuzcoa. Arch Bronconeumol, 34:23-7.
49. Mawar N, Saha S, Pandit A, et al. 2005. The third phase of HIV pandemic: social consequences of HIV/AIDS stigma and discrimination and future needs. Indian J Med Resp, 122:471-84.
50. Menezes AM, Perez-Padilla R, Jardim JB, et al. 2005. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalenee study. Lancet, 366:1875-81.
51. [MHM and AMMMTS] Ministry of Health of Malaysia, Academy of Medicine of Malaysia and Malaysian Thoracic Society. 1999. Guidelines in the management of chronic obstructive pulmonary disease. A consensus statement. Med J Malaysia, 54:387-401.
52. Mueller RE, Keble DL, Plummer J, et al. 1971. The prevalence of chronic bronchitis, chronic airway obstruction, and respiratory symptoms in a Colorado city. Am Rev Respir Dis, 103:209-28.
53. [MHLBI] National Heart, Lung and Blood Institute. 1998. Morbidity and mortality: 1998 Chartbook on cardiovascular, lung, and blood diseases. Bethesda MD: US Department, of Health and Human Services, Public Health Service, National Institutes of Health.
54. Neffen H, Fritsher C, Schacht FC, et al; AIRLA Survey Group. 2005. Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica, 17:191-7.
55. Ni Chroinin M, Greenstone IR, Ducharme FM. 2004. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Cochrane Database Syst Rev, 4:CD005307.
56. Ni Chroinin M, Greenstone IR, Danish A, et al. 2005. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev, 4: CD005535.
57. Oostenbrink JB, Rutten-van Mölken MP, Noord JA, et al. 2004. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonay disease, Eur Respir J, 23:241-9.
58. Oostenbrink JB, Rutten-van Molken MP. 2004. Resource use and risks factors in high-cost exacerbations of COPD. Respir Med, 98 (9): 883-91.
59. Ottmani SE, Sherpbier R, Pio A, et al. 2005. Practical Approach to Lung Health (PAL): A primary health care strategy for the integrated management of respiratory conditions in people five years of age and over. Geneva: World Health Organization. WHO/HTM/TB/2005.351.
60. Paggiaro PL, Dahle R, Bakran I, et al. 1998. Multicentre randomised placebo-controlled trial of inhaled fluticasone in patients with COPD. International COPD study group. Lancet, 14:773-80.
61. Perera BJ. 1995. Efficacy and cost effectiveness of inhaled steroids in asthma in developing countries. Arch Dis Child, 72:312-16.
62. Price MJ, Briggs AH. 2002. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmaconeconomics, 20:183-94.
63. Rabe KF, Vermeire PA, Soriano JB, et al. 2000. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J, 16:802.
64. Rabe KF, Adachi M, Lai CKW et al. 2004. Worldwide severity and control of asthma in children and adults: the Global Asthma Insights and Reality Surveys. J Allergy Clin Immunol, 114:40-7.
65. Rea H, McAuley S, Stewart A, et al. 2004. A chronic disease management programme can reduce days hospital for patients with COPD. Intern Med J, 34:608-14.
66. [SAPS] Working Group of the South African Pulmonary Society. 1998. Guidelines for the management of chronic obstructive pulmonary disease. South African Med J, 88:8.
67. Schelledy DC, McCormick SR, LeGrand TS, et al. 2005. The effect of a pediatric asthma management program provided by respiratory therapists and patient outcomes and costs. Heart Lung, 34:423-8.
68. Simonella L, Marks G, Sanderson K. 2006. Cost-effectiveness of current and optimal treatment for adult asthma. Intern Med, J, 36:244.
69. Slama K, Karsenty S, Hirsch A. 1995. Effectiveness of minimal intervention by general practitioners with their smoking patients: a randomised, controlled trial in France. Tob Control, 4:162-9.
70. Slama K. 1998. Tobacco control and prevention. A guide for low income countries. Paris: International Union against Tuberculosis and Lung Disease. URL at http://www.iuatld.org/.
71. Sterk PJ, Buist SA, Woolcock AJ, Marks GB, et al. 1999. The message from the 1998 World Asthma Meeting. Eur Respir J, 14:1435-53.
72. [UNDP] United Nations Development Programme. 1997. Human development report 1997. Human development to eradicate poverty [French]. Paris: Editions Economica.
73. Vanable PA, Carey MP, Blair DC, et al. 2006. Impact of HIV-related stigma on health behaviors and psychological adjustment among HIV-positive men and women. AIDS Behav, 10:473-82.
74. Viegi G, Pedreschi M, Pistelli F, et al. 2000. Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest, 117(5 Suppl 2):339S-45S.
75. Von Hertzen L, Reunanen A, Impivaara O, et al. 2000. Airway obstruction in relation to symptoms in chronic respiratory disease - a nationally representative population study. Respir Med, 94:356-63.
76. Wan, Aït-Khaled N. 2006. Dissemination and implementation of Asthma Guidelines. State of the Art. Inter J Tuberc Lung Dis, 10:710-16
77. Weiss KB, Sullivan SD. 2001. The health economics of asthma and rhinitis. Assessing the economic impact. J Allergy Clin Immunol, 107:3-8.
78. World Bank. 1993. World Development Report 1993: Investing in Health. World Bank Publication.
79. [WHO] World Health Organization. 1999. Framework convention on tobacco control. Technical Briefing Series. WHO/NCD/TF1/99.1-7
80. [WHO] World Health Organization. 2004. The World Health Report 2004: changing history. Statistical Annex 127-131. Geneva: World Health Organization.
81. [WHO] World Health Organization. 2005. Preventing chronic diseases: a vital investment [online]. Geneva: World Health Organization. Accessed on November 8, 2006. URL: http://www.who.int/chp/ chronic_disease_repotr/contents/en/index.html.
82. Wouters EF. 2003. Economic analysis of the confronting COPD survey: an overview of results. Respir Med, 97(suppl C):S3-14
83. Yach D. 1996. Le tabac en Afrique. Forum Mondial de la Santé, 17:30-8.